Tags

Type your tag names separated by a space and hit enter

[Active tobacco smoking as determinant of costs of inpatient treatment of COPD exacerbations].
Przegl Lek. 2004; 61(10):1049-51.PL

Abstract

The aim of the study was assessment of the influence of tobacco smoking on direct costs of in-hospital treatment of chronic obstructive pulmonary disease exacerbations (COPD). 112 men who underwent in-hospital treatment of exacerbation of moderate COPD in the years 2001-2002 were included in the study. The patients were qualified into one of three groups: I--never-smoking patients (n=40); II--former smokers (n=42); III--active smokers (n=30). The mean age of patients was 70.9 +/- 8.9 years (I--74.8 +/- 7.4; II--68.4 +/- 9.4; III--69.4 +/- 9.8). The mean direct cost of COPD patient treatment was PLN 2162.00 +/- 920.90 (I--PLN 2025.50 +/- 681.30; II--PLN 1875.80 +/- 608.70; III--PLN 2744.60 +/- 1266.20). The mean period of smoking was 18.3 pack-years in the group II and 27.7 pack-years in the group III. No significant differences in FEV1 were found between the groups. No significant differences were found in the treatment costs between the groups I and II. It was demonstrated that the costs of in-hospital COPD treatment are significantly higher in the group III than in the groups I and II. A linear regression formula was calculated, showing a linear relationship between each consecutive pack-year of addiction and the costs of exacerbation treatment in the group III (R=0.39, R2=0.13, standardized BETA index = 24.0; p<0.03). No similar relationship was found in the former smokers' group. The analysis of the data shows that: (1) active tobacco smoking by patients is related to significantly higher direct costs of in-hospital treatment of COPD exacerbations than in case of never-smoking patients or patients who smoked in the past, and (2) the costs of in-hospital treatment of COPD exacerbations in case of people who have stopped smoking are comparable to the costs of hospitalization of never-smoking patients with COPD.

Authors+Show Affiliations

Klinika Chorób Wewnetrznych, Pneumonologii i Alergologii Centralnego Szpitala Klinicznego Ministerstwa Obrony Narodowej, Wojskowy Instytut Medyczny w Warszawie. targowski.tomasz@xl.wp.plNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
English Abstract
Journal Article

Language

pol

PubMed ID

15794248

Citation

Targowski, Tomasz, et al. "[Active Tobacco Smoking as Determinant of Costs of Inpatient Treatment of COPD Exacerbations]." Przeglad Lekarski, vol. 61, no. 10, 2004, pp. 1049-51.
Targowski T, Jahnz-Rózyk K, From S, et al. [Active tobacco smoking as determinant of costs of inpatient treatment of COPD exacerbations]. Prz Lek. 2004;61(10):1049-51.
Targowski, T., Jahnz-Rózyk, K., From, S., & Płusa, T. (2004). [Active tobacco smoking as determinant of costs of inpatient treatment of COPD exacerbations]. Przeglad Lekarski, 61(10), 1049-51.
Targowski T, et al. [Active Tobacco Smoking as Determinant of Costs of Inpatient Treatment of COPD Exacerbations]. Prz Lek. 2004;61(10):1049-51. PubMed PMID: 15794248.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Active tobacco smoking as determinant of costs of inpatient treatment of COPD exacerbations]. AU - Targowski,Tomasz, AU - Jahnz-Rózyk,Karina, AU - From,Sławomir, AU - Płusa,Tadeusz, PY - 2005/3/30/pubmed PY - 2005/7/19/medline PY - 2005/3/30/entrez SP - 1049 EP - 51 JF - Przeglad lekarski JO - Prz. Lek. VL - 61 IS - 10 N2 - The aim of the study was assessment of the influence of tobacco smoking on direct costs of in-hospital treatment of chronic obstructive pulmonary disease exacerbations (COPD). 112 men who underwent in-hospital treatment of exacerbation of moderate COPD in the years 2001-2002 were included in the study. The patients were qualified into one of three groups: I--never-smoking patients (n=40); II--former smokers (n=42); III--active smokers (n=30). The mean age of patients was 70.9 +/- 8.9 years (I--74.8 +/- 7.4; II--68.4 +/- 9.4; III--69.4 +/- 9.8). The mean direct cost of COPD patient treatment was PLN 2162.00 +/- 920.90 (I--PLN 2025.50 +/- 681.30; II--PLN 1875.80 +/- 608.70; III--PLN 2744.60 +/- 1266.20). The mean period of smoking was 18.3 pack-years in the group II and 27.7 pack-years in the group III. No significant differences in FEV1 were found between the groups. No significant differences were found in the treatment costs between the groups I and II. It was demonstrated that the costs of in-hospital COPD treatment are significantly higher in the group III than in the groups I and II. A linear regression formula was calculated, showing a linear relationship between each consecutive pack-year of addiction and the costs of exacerbation treatment in the group III (R=0.39, R2=0.13, standardized BETA index = 24.0; p<0.03). No similar relationship was found in the former smokers' group. The analysis of the data shows that: (1) active tobacco smoking by patients is related to significantly higher direct costs of in-hospital treatment of COPD exacerbations than in case of never-smoking patients or patients who smoked in the past, and (2) the costs of in-hospital treatment of COPD exacerbations in case of people who have stopped smoking are comparable to the costs of hospitalization of never-smoking patients with COPD. SN - 0033-2240 UR - https://www.unboundmedicine.com/medline/citation/15794248/[Active_tobacco_smoking_as_determinant_of_costs_of_inpatient_treatment_of_COPD_exacerbations]_ L2 - https://medlineplus.gov/copd.html DB - PRIME DP - Unbound Medicine ER -